NYSE$AMRX
Amneal Pharmaceuticals Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Amneal's third quarter results reflect solid performance across its diversified portfolio, driven by new product innovation, leveraging key capabilities, and strong execution.
Amneal Pharmaceuticals reported its Q3 2022 financial results with net revenue of $546 million, a GAAP net loss of $3 million, and an adjusted EBITDA of $126 million. The company is maintaining its full year 2022 outlook.
- Net revenue in Q3 2022 was $546 million, a 3.2% increase compared to Q3 2021.
- GAAP Net loss attributable to Amneal Pharmaceuticals, Inc. was $3 million in Q3 2022 compared to a net loss of $4 million in Q3 2021.
- Adjusted EBITDA in Q3 2022 was $126 million, a decrease of 5.1% compared to Q3 2021, reflective of investments to drive upcoming new product launches.
- Diluted loss per share and adjusted diluted EPS in Q3 2022 were $(0.02) and $0.14, respectively, compared to $(0.03) and $0.21, respectively, in Q3 2021.
Headline financials
Revenue & EPS history
Amneal · Revenue · Quarterly
$546M
Revenue by segment
Amneal · $546M total across 3 segments · Q3 2022
- Affordable Medicines$350M—64.2%
- AvKARE$106M+19.3%19.4%
- Specialty$89.5M-3.5%16.4%
Forward guidance
The Company is maintaining its previously provided full year 2022 guidance.
Tailwinds
- Net revenue $2.15 billion - $2.25 billion
- Adjusted EBITDA $500 million - $520 million
- Adjusted diluted EPS $0.65 - $0.70
- Operating cash flow $200 million - $225 million
- Capital expenditures $65 million - $75 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-0.6%
Avg return
Earnings day
-3.2%
Avg return
5 days after
+0.4%
Avg return
30 days after
54%
20 / 37 earnings
Positive
+36.6%
Q2 2023
Best reaction
-23.0%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -7.6% | +0.9% | |
| Q4 2025 | -4.6% | -8.2% | -18.2% | |
| Q3 2025 | -4.1% | +8.8% | +20.0% | |
| Q1 2025 | +3.0% | -6.7% | -5.4% | |
| Q4 2024 | +3.5% | +7.0% | -1.2% | |
| Q3 2024 | +6.9% | +4.9% | -1.9% | |
| Q2 2024 | +12.9% | +9.6% | +21.9% | |
| Q1 2024 | +7.1% | +6.1% | +7.6% | |
| Q4 2023 | -2.2% | -3.8% | +9.8% | |
| Q3 2023 | -3.6% | +0.2% | +11.4% | |
| Q2 2023 | +36.6% | +25.9% | +25.6% | |
| Q1 2023 | +9.8% | -3.3% | +38.6% | |
| Q4 2022 | -8.1% | -15.8% | -33.5% | |
| Q3 2022 | +13.0% | +8.2% | +16.8% | |
| Q2 2022 | -9.5% | -9.2% | -36.4% | |
| Q1 2022 | -11.5% | -22.2% | -13.0% | |
| Q4 2021 | -7.0% | -12.4% | -3.4% | |
| Q3 2021 | -12.5% | -9.8% | -29.0% | |
| Q2 2021 | +4.5% | +4.9% | +6.6% | |
| Q1 2021 | -8.1% | -8.0% | -5.5% | |
| Q4 2020 | +5.9% | +0.0% | +40.1% | |
| Q3 2020 | -15.0% | -15.6% | -14.6% | |
| Q2 2020 | -16.3% | -19.9% | -30.7% | |
| Q1 2020 | +20.3% | +16.1% | +42.5% | |
| Q4 2019 | -20.4% | -16.4% | -37.0% | |
| Q3 2019 | -23.0% | -23.0% | +7.0% | |
| Q2 2019 | -8.0% | -10.5% | -18.5% | |
| Q1 2019 | -20.7% | -31.0% | -41.8% | |
| Q4 2018 | +8.4% | +2.0% | +13.8% | |
| Q3 2018 | +5.1% | +4.6% | -9.1% | |
| Q2 2018 | +0.6% | +9.8% | +19.4% | |
| Q1 2018 | +1.5% | +13.3% | +30.2% | |
| Q4 2017 | +4.4% | — | — | |
| Q3 2017 | +5.9% | — | — | |
| Q2 2017 | +1.5% | — | — | |
| Q1 2017 | -3.2% | — | — | |
| Q4 2016 | +2.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro